371 related articles for article (PubMed ID: 29103998)
1. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
[TBL] [Abstract][Full Text] [Related]
2. Combination of TLR8 and TLR4 agonists reduces the degrading effects of nicotine on DC-NK mediated effector T cell generation.
Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
Int Immunopharmacol; 2018 Aug; 61():54-63. PubMed ID: 29803914
[TBL] [Abstract][Full Text] [Related]
3. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells.
Krumbiegel D; Zepp F; Meyer CU
Hum Immunol; 2007 Oct; 68(10):813-22. PubMed ID: 17961769
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.
Tada H; Aiba S; Shibata K; Ohteki T; Takada H
Infect Immun; 2005 Dec; 73(12):7967-76. PubMed ID: 16299289
[TBL] [Abstract][Full Text] [Related]
5. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
[TBL] [Abstract][Full Text] [Related]
6. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.
Lebedeva E; Bagaev A; Pichugin A; Chulkina M; Lysenko A; Tutykhina I; Shmarov M; Logunov D; Naroditsky B; Ataullakhanov R
BMC Immunol; 2018 Jul; 19(1):26. PubMed ID: 30055563
[TBL] [Abstract][Full Text] [Related]
7. The genetic background influences the cellular and humoral immune responses to vaccines.
Zeng M; Nourishirazi E; Guinet E; Nouri-Shirazi M
Clin Exp Immunol; 2016 Nov; 186(2):190-204. PubMed ID: 27393001
[TBL] [Abstract][Full Text] [Related]
8. Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells.
Chen XZ; Mao XH; Zhu KJ; Jin N; Ye J; Cen JP; Zhou Q; Cheng H
Arch Dermatol Res; 2010 Jan; 302(1):57-65. PubMed ID: 19578865
[TBL] [Abstract][Full Text] [Related]
9. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways.
Sawaki J; Tsutsui H; Hayashi N; Yasuda K; Akira S; Tanizawa T; Nakanishi K
Int Immunol; 2007 Mar; 19(3):311-20. PubMed ID: 17289654
[TBL] [Abstract][Full Text] [Related]
10. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
11. R848/TLR7-Mediated Stronger CD8+ T Immunity Is Dependent on DC-NK Cell Interactions.
Zhou J; Nouri-Shirazi M; Tang H; Shen Y; Zeng M
Int Arch Allergy Immunol; 2022; 183(8):860-875. PubMed ID: 35263757
[TBL] [Abstract][Full Text] [Related]
12. Modification of TLR-induced activation of human dendritic cells by type I IFN: synergistic interaction with TLR4 but not TLR3 agonists.
Walker J; Tough DF
Eur J Immunol; 2006 Jul; 36(7):1827-36. PubMed ID: 16783851
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.
Loré K; Betts MR; Brenchley JM; Kuruppu J; Khojasteh S; Perfetto S; Roederer M; Seder RA; Koup RA
J Immunol; 2003 Oct; 171(8):4320-8. PubMed ID: 14530357
[TBL] [Abstract][Full Text] [Related]
14. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
[TBL] [Abstract][Full Text] [Related]
15. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells.
Re F; Strominger JL
J Immunol; 2004 Dec; 173(12):7548-55. PubMed ID: 15585882
[TBL] [Abstract][Full Text] [Related]
16. Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.
van Haren SD; Dowling DJ; Foppen W; Christensen D; Andersen P; Reed SG; Hershberg RM; Baden LR; Levy O
J Immunol; 2016 Dec; 197(11):4413-4424. PubMed ID: 27793997
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma.
Kamath AT; Sheasby CE; Tough DF
J Immunol; 2005 Jan; 174(2):767-76. PubMed ID: 15634897
[TBL] [Abstract][Full Text] [Related]
18. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
19. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.
Boullart AC; Aarntzen EH; Verdijk P; Jacobs JF; Schuurhuis DH; Benitez-Ribas D; Schreibelt G; van de Rakt MW; Scharenborg NM; de Boer A; Kramer M; Figdor CG; Punt CJ; Adema GJ; de Vries IJ
Cancer Immunol Immunother; 2008 Nov; 57(11):1589-97. PubMed ID: 18322684
[TBL] [Abstract][Full Text] [Related]
20. Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.
Toka FN; Nfon CK; Dawson H; Golde WT
Clin Vaccine Immunol; 2009 Jun; 16(6):866-78. PubMed ID: 19369481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
